Franklin Chen

827 total citations
17 papers, 541 citations indexed

About

Franklin Chen is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Franklin Chen has authored 17 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Franklin Chen's work include Cancer Immunotherapy and Biomarkers (5 papers), Orthopedic Surgery and Rehabilitation (4 papers) and Genetic factors in colorectal cancer (3 papers). Franklin Chen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Orthopedic Surgery and Rehabilitation (4 papers) and Genetic factors in colorectal cancer (3 papers). Franklin Chen collaborates with scholars based in United States, France and Germany. Franklin Chen's co-authors include Kenneth A. Krackow, David M. Kalainov, Richard L. Makowiec, Michael A. Mont, David S. Hungerford, Marc W. Hungerford, A. Lee Dellon, Brad A. Myers, David Yaron and Matthew H. Taylor and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Bone and Joint Surgery and Clinical Orthopaedics and Related Research.

In The Last Decade

Franklin Chen

17 papers receiving 512 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franklin Chen United States 12 311 153 112 100 96 17 541
Naomasa Fukase Japan 13 201 0.6× 70 0.5× 19 0.2× 88 0.9× 19 0.2× 41 423
A. König Germany 14 205 0.7× 96 0.6× 57 0.5× 19 0.2× 29 0.3× 35 704
Yasuhiro Saegusa Japan 11 194 0.6× 33 0.2× 57 0.5× 25 0.3× 17 0.2× 36 482
Juan Sanchís Spain 10 136 0.4× 108 0.7× 24 0.2× 48 0.5× 12 0.1× 40 379
Guanyu Yu China 13 160 0.5× 146 1.0× 24 0.2× 110 1.1× 7 0.1× 43 456
K Nagata Japan 12 204 0.7× 77 0.5× 14 0.1× 55 0.6× 23 0.2× 32 396
Jin-Xing Zhang China 11 63 0.2× 35 0.2× 74 0.7× 89 0.9× 18 0.2× 30 304
Susan Y. Quan United States 8 85 0.3× 96 0.6× 12 0.1× 69 0.7× 61 0.6× 20 357
Shu Kobayashi Japan 17 384 1.2× 76 0.5× 31 0.3× 25 0.3× 8 0.1× 60 691
Iori Takigami Japan 14 280 0.9× 59 0.4× 103 0.9× 71 0.7× 6 0.1× 33 513

Countries citing papers authored by Franklin Chen

Since Specialization
Citations

This map shows the geographic impact of Franklin Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franklin Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franklin Chen more than expected).

Fields of papers citing papers by Franklin Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franklin Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franklin Chen. The network helps show where Franklin Chen may publish in the future.

Co-authorship network of co-authors of Franklin Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Franklin Chen. A scholar is included among the top collaborators of Franklin Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franklin Chen. Franklin Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Overman, Michael J., Heinz‐Josef Lenz, Thierry André, et al.. (2022). Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.. Journal of Clinical Oncology. 40(16_suppl). 3510–3510. 25 indexed citations
2.
Kaur, Kawaljit, Meng-Wei Ko, Franklin Chen, & Anahid Jewett. (2021). Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer. Cancer Immunology Immunotherapy. 71(5). 1033–1047. 12 indexed citations
3.
Overman, Michael J., Francesca Bergamo, Ray McDermott, et al.. (2018). Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. Journal of Clinical Oncology. 36(4_suppl). 554–554. 38 indexed citations
4.
Hassan, Raffit, Anish Thomas, John Nemunaitis, et al.. (2018). Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology. 36(5_suppl). 166–166. 6 indexed citations
5.
Hassan, Raffit, Anish Thomas, John Nemunaitis, et al.. (2018). Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.. Journal of Clinical Oncology. 36(15_suppl). 8563–8563. 4 indexed citations
6.
Jérusalem, Guy, Franklin Chen, David R. Spigel, et al.. (2017). OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S252–S252. 19 indexed citations
7.
Chen, Franklin & David M. Kalainov. (2017). Phalanx fractures and dislocations in athletes. Current Reviews in Musculoskeletal Medicine. 10(1). 10–16. 5 indexed citations
8.
9.
Hassan, Raffit, Anish Thomas, Manish R. Patel, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology. 34(15_suppl). 8503–8503. 53 indexed citations
10.
Verschraegen, Claire F., Franklin Chen, David R. Spigel, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology. 34(15_suppl). 9036–9036. 25 indexed citations
11.
Kalainov, David M., et al.. (2011). Complications of K-Wire Fixation in Procedures Involving the Hand and Wrist. The Journal Of Hand Surgery. 36(4). 610–616. 127 indexed citations
12.
Chen, Franklin, et al.. (2009). Strain Energy in Organic Compounds: Bomb Calorimetry. Journal of Chemical Education. 86(6). 764–764. 3 indexed citations
13.
Leitermann, Randy J., Maia Terashvili, Hirokazu Mizoguchi, et al.. (2004). Increased release of immunoreactive dynorphin A1–17 from the spinal cord after intrathecal treatment with endomorphin-2 in anesthetized rats. European Journal of Pharmacology. 504(3). 177–183. 11 indexed citations
14.
Chen, Franklin, Brad A. Myers, & David Yaron. (2000). Using Handheld Devices for Tests in Classes. Defense Technical Information Center (DTIC). 23 indexed citations
15.
Chen, Franklin, Randall W. Culp, Lawrence H. Schneider, & A. Lee Osterman. (1998). Revision of the ununited one-bone forearm. The Journal Of Hand Surgery. 23(6). 1091–1096. 20 indexed citations
16.
Mont, Michael A., A. Lee Dellon, Franklin Chen, et al.. (1996). The Operative Treatment of Peroneal Nerve Palsy*. Journal of Bone and Joint Surgery. 78(6). 863–9. 117 indexed citations
17.
Chen, Franklin & Kenneth A. Krackow. (1994). Management of Tibial Defects in Total Knee Arthroplasty A Biomechanical Study. Clinical Orthopaedics and Related Research. 305(305). 249???257–249???257. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naomasa Fukase Breakdown of academic impact, for papers by A. König Breakdown of academic impact, for papers by Yasuhiro Saegusa Breakdown of academic impact, for papers by Juan Sanchís Breakdown of academic impact, for papers by Guanyu Yu Breakdown of academic impact, for papers by K Nagata Breakdown of academic impact, for papers by Jin-Xing Zhang Breakdown of academic impact, for papers by Susan Y. Quan Breakdown of academic impact, for papers by Shu Kobayashi Breakdown of academic impact, for papers by Iori Takigami
Rankless by CCL
2026